Ameriprise
CRNX

Ameriprise’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ameriprise’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.6M Sell
497,205
-301,129
-38% -$11.2M ﹤0.01% 1585
2026
Q1 		$29M Buy
798,334
+197,144
+33% +$8.81M 0.01% 1171
2025
Q4 		$28M Sell
601,190
-13,626
-2% -$607K 0.01% 1182
2025
Q3 		$25.6M Buy
614,816
+376,206
+158% +$12M 0.01% 1230
2025
Q2 		$6.86M Buy
238,610
+33,556
+16% +$1.04M ﹤0.01% 2101
2025
Q1 		$6.88M Sell
205,054
-150,120
-42% -$5.61M ﹤0.01% 2059
2024
Q4 		$18.2M Buy
355,174
+186,681
+111% +$10.4M ﹤0.01% 1393
2024
Q3 		$8.61M Buy
168,493
+143,695
+579% +$7.41M ﹤0.01% 1927
2024
Q2 		$1.11M Buy
+24,798
New +$1.15M ﹤0.01% 3123

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise's CRNX Position: Q2 2026 in Review

Ameriprise reduced its Crinetics Pharmaceuticals (CRNX) stake by 38% in Q2 2026, selling an estimated $11.2M and leaving 497,205 shares worth $18.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1585.

Ameriprise first reported a position in CRNX in Q2 2024 and has held it in 9 quarters since. The position peaked at $29M in Q1 2026. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Ameriprise held 497,205 shares of Crinetics Pharmaceuticals worth $18.6M as of Q2 2026.
  • Ameriprise sold 301,129 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $11.2M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1585 holding.
  • Ameriprise first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Ameriprise's Crinetics Pharmaceuticals position peaked at $29M in Q1 2026.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.